Q-Line BiotechNSE:QLINE -5.15%12 PB Ratio is 6.71 as of Jun. 29, 2026, which is 7% above its 10-year median of 6.25. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Q-Line Biotech ranks worse than 85.5% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Q-Line Biotech's share price is ₹546.50. Q-Line Biotech's Book Value per Share for the quarter that ended in Mar. 2025 was ₹81.42. Hence, Q-Line Biotech's PB Ratio of today is 6.71.
The historical rank and industry rank for Q-Line Biotech's PB Ratio or its related term are showing as below:
NSE:QLINE'
s PB Ratio Range Over the Past 10 Years
Min: 5.83 Med: 6.25 Max: 6.91
Current: 6.71
During the past 3 years, Q-Line Biotech's highest PB Ratio was 6.91. The lowest was 5.83. And the median was 6.25.
NSE:QLINE's PB Ratio is ranked worse than 85.5% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.015
vs NSE:QLINE: 6.71
During the past 12 months, Q-Line Biotech's average Book Value Per Share Growth Rate was 17.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Q-Line Biotech PB Ratio Related Terms
Q-Line Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech PB Ratio Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
PB Ratio
0.00
0.00
0.00
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
PB Ratio
0.00
0.00
0.00
NSE:QLINE vs ABT, SYK, MDT: PB Ratio Comparison
For the Medical Devices subindustry, Q-Line Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Q-Line Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Q-Line Biotech (NSE:QLINE) has a PB Ratio of 6.71 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Q-Line Biotech and its competitors. This is near median its historical median of 6.25. Over the past decade, Q-Line Biotech's PB Ratio has ranged from 5.83 to 6.91. According to the industry distribution chart, Q-Line Biotech ranks #672 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 85.5%.
Is Q-Line Biotech's PB Ratio too high?
Q-Line Biotech's current PB Ratio of 6.71 is near median its 10-year median of 6.25. Over the past 10 years, this metric has ranged from a low of 5.83 to a high of 6.91. The Medical Devices & Instruments industry median PB Ratio is 2.02. Q-Line Biotech's value of 6.71 is 233% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #672 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #672 out of 786 companies for PB Ratio. This places Q-Line Biotech in the lower half of its industry. The industry median PB Ratio is 2.02. Q-Line Biotech's value of 6.71 is 233% above this benchmark. Historically, Q-Line Biotech's own PB Ratio has ranged from 5.83 to 6.91 over the past decade. While the company's 10-year median is 6.25 vs. the industry median of 2.02, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current PB Ratio of 6.71 is 233% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current PB Ratio is 6.71, which is near median its own 10-year median of 6.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current PB Ratio of 6.71. The current PB Ratio is 6.71, which is near median its 10-year median of 6.25 and 233% above the Medical Devices & Instruments industry median of 2.02. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current PB Ratio is 6.71 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 